Immuneel Therapeutics is developing Chimeric Antigen Receptor T cell (CAR-T) therapies to provide affordable and accessible cell and gene treatments for cancer patients in India. The startup addresses the lack of advanced cancer therapies in the country, aiming to improve patient outcomes through personalized immunotherapy.
Funding
$38M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients in India lack access to advanced cell and gene therapies, which are often unavailable or prohibitively expensive. This limits treatment options and contributes to poorer outcomes for a significant portion of the population affected by cancer.
Solution
Immuneel Therapeutics is developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to provide affordable and accessible cell and gene treatments for cancer patients in India. The company is pioneering the use of genetically modified human immune cells to target and fight cancer. By focusing on affordability and accessibility, Immuneel aims to address the unmet needs of India’s cancer patients and improve access to advanced treatment options. The therapies are being developed with the goal of offering hope to patients who may not have had access to such treatments previously.
Target Audience
The primary target audience is cancer patients in India who lack access to advanced and affordable cell and gene therapies.
Features
- Development of Chimeric Antigen Receptor T-cell (CAR-T) therapies
- Focus on making cell and gene therapies affordable and accessible in India
- Utilizing genetically modified human immune cells to fight cancer
- Aiming to address the unmet needs of India’s cancer patients